


Psychedelic Drug in Early Stages of Development Could Have Potential for Postpartum Depression

October 28, 2021



Nathan Bryson, PhD, chief scientific officer of Field Trip Health, said the company's new psychedelic compound, FT-104, could have potential uses in the treatment of postpartum depression.



In an interview with *Pharmacy Times*, Nathan Bryson, PhD, chief scientific officer of Field Trip Health, said the company's new psychedelic compound, FT-104, could have potential uses in the treatment of postpartum depression.

Bryson said patients with postpartum depression are in dire need of new treatments, since the 2 existing options either take 6 to 8 weeks to be effective or require a 3-day hospital stay for an infusion, which separates the mother from the infant and can result in more stress on both. Although it is still in early stages of development, Bryson said FT-104 would be administered over the course of about a day in a clinic environment, and would be out of the mother's system within 24 hours, allowing her to begin breastfeeding again. If successful, this drug could be a major development in the treatment paradigm for postpartum depression, Bryson said.

Related Content:

[Mental Health](#) | [Women's Health](#) | [Specialty Pharmacy](#)

[Neuroendocrine Tumors Are Characterized by Heterogeneity, Ability to Occur Anywhere in the Body](#)

[WHO Calls for Development of Maternal Vaccine Against GBS](#)

[Pharmacy Clinical Pearl of the Day: Ectopic Pregnancy](#)

Neuroendocrine Tumors Are Characterized by Heterogeneity, Ability to Occur Anywhere in the Body

November 4, 2021



Mei Ka Fong Seg 2



In an interview with Pharmacy Times about her presentation at the North American Neuroendocrine Tumor Society (NANETS) 2021 neuroendocrine tumor (NET) Medical Symposium, Mei Ka Fong, PharmD, BCOP, said there are 3 key issues that differentiate NETs from other types of tumors.

Firstly, Fong pointed out that NETs can occur almost anywhere in the body, although they are most common in the gastrointestinal tract and lungs. She also said the grading of NETs allows for a wide range of treatments, and burden of disease can also range from asymptomatic to a high burden.

Related Content:

[NANETS Annual Multidisciplinary NET Medical Symposium](#) | [Oncology](#) | [Specialty Pharmacy](#) | [Hospital](#) | [Conference](#)

[Pharmacy Clinical Pearl of the Day: Ectopic Pregnancy.](#)

[FDA Accepts BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma](#)

[Expert: Neuroendocrine Tumor Treatment Can Take Multiple Forms](#)

